LZTS1-AS1: A Potential Drug Target and Biomarker (G100874051)

Target Name: LZTS1-AS1

NCBI ID: G100874051

LZTS1-AS1

Other Name(s): LZTS1 antisense RNA 1

LZTS1-AS1: A Potential Drug Target and Biomarker

LZTS1-AS1, also known as LZT1-AS1, is a protein that is expressed in the brain and has been shown to play a role in various neurological disorders, including Alzheimer's disease. The research on LZTS1-AS1 has led to the possibility that it could be a drug target or biomarker for the treatment of these disorders.

Expression of LZTS1-AS1

LZTS1-AS1 is a protein that is expressed in the brain and has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is found in the brain, and its levels have been shown to increase in individuals with Alzheimer's disease.

In addition, LZTS1-AS1 has been shown to be involved in the regulation of important cellular processes in the brain, including the regulation of neurotransmitter release and the maintenance of the blood-brain barrier. These functions are critical for maintaining the health and function of the brain, and are potentially important for the development and progression of Alzheimer's disease.

Potential as a drug target

The potential use of LZTS1-AS1 as a drug target is based on its involvement in the regulation of important cellular processes in the brain. Alzheimer's disease is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, which are thought to contribute to the development and progression of the disease.

In addition, LZTS1-AS1 has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of the brain. The regulation of neurotransmitter release is critical for maintaining the health and function of the brain, and is potentially important for the development and progression of Alzheimer's disease.

Potential as a biomarker

The potential use of LZTS1-AS1 as a biomarker for Alzheimer's disease is based on its expression in the brain and its potential involvement in the development and progression of the disease. Alzheimer's disease is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, which are thought to contribute to the development and progression of the disease.

In addition, LZTS1-AS1 has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of the brain. The regulation of neurotransmitter release is critical for maintaining the health and function of the brain, and is potentially important for the development and progression of Alzheimer's disease.

Conclusion

LZTS1-AS1 is a protein that is expressed in the brain and has been shown to play a role in various neurological disorders, including Alzheimer's disease. The research on LZTS1-AS1 has led to the possibility that it could be a drug target or biomarker for the treatment of these disorders. Further research is needed to confirm these potential uses and to develop safe and effective treatments for Alzheimer's disease.

Protein Name: LZTS1 Antisense RNA 1

The "LZTS1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LZTS1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets